🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization marks a significant shift in the management of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Global Access

According to data published in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This establishes an comparable level with the current standard treatment, which combines a dual-drug approach. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in many regions with limited resources.

Doctors treating patients have expressed positive views. Access to a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.